Dr. Grant brings to the table significant BOD governance, global business development, and corporate development expertise.

Half Moon Bay, CA. – January 10, 2023 – Life Science Newswire –GenNext Technologies, Inc., an innovative provider of laboratory tools for advanced structural characterization of proteins, announced today that Dr. John L. Grant has joined its Board of Directors.

Dr. Grant served as a highly valuable mentor for GenNext during the BioTools Innovation 2022 Cohort Program where the company was selected as the Grand Prize Winner. During this intensive collaboration, Dr. Grant gained exposure to the GenNext team and technology, ultimately deciding to take on a more formal role as an advisor on the BOD.

Currently, Dr. Grant is the principal of Lemnos Advisory, LLC, which provides insights into strategic topics and corporate development for operating companies, transaction advisors, investment banks, and venture investors. He also holds various director and advisor positions in technology-intensive startups and non-profit BODs, mentors and judges for venture accelerators, and invests with multiple angel groups.

Previously, Dr. Grant led global strategy and external business development in several 3M divisions within the Healthcare and Industrial Business Groups. He led and participated in 25 acquisitions, divestitures, and minority corporate venture investments. Earlier, he held managerial positions in product and technology development, quality management, strategic marketing, and business management.

Dr. Grant’s earned an MBA from the Carlson School of Management at the University of Minnesota and a PhD from Northwestern University. He is a member of the National Association of Corporate Directors and has earned the NACD Certified Director designation.

“GenNext has two critical elements in its favor. An experienced, cross-disciplinary team with a very positive culture. And truly novel and highly valuable technology.” Dr Grant went on to say, “I’m impressed with team’s ability to gain grants from the NIH and generate commercial sales. I look forward to participating in the continued success of this capable and ambitious company.”

Scot Weinberger, Founder and CEO of GenNext explained, “With having established commercial momentum and adding next generation elements to our offering, the time is right for John to join our governance team. With John’s valuable business acumen, combined with his understanding of the underlying science and technology behind our products, I am assured that he will make significant contributions to our expansion."

For more information, please visit www.gnxtech.com and follow @GenNext_Tech on Twitter and on Linkedin.

About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, compact, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug therapies that improve human health.